Skip to main content
Equibles
INDV logo

INDV · Indivior Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio

Track INDV — free

Use INDV with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INDV.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$35.38 -0.47 (-1.31%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$4.23B
Shares
118.01M
Volume · Oct 1 215.48K Avg daily vol (3M) 2.03M

Indivior Pharmaceuticals, Inc. Earnings Call Transcripts

Quarterly earnings calls for Indivior Pharmaceuticals, Inc. (INDV), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▼6.3% $266.00M $47.00M '25 Q1 25-04-24 ▲1% $302.00M $18.00M '25 Q2 25-07-31 ▲2.3% $314.00M $42.00M '25 Q3 25-10-30 ▲19.8% $357.00M $103.00M '25 Q4 26-02-26 ▲19.2% $317.00M $89.00M '26 Q1 26-04-30 LATEST ▲13.6% $343.00M $122.00M '26 Q2 26-08-03
Earnings call
FY26 · Q2
2026-08-03
Indivior Pharmaceuticals, Inc. (INDV) Q2 2026 Earnings Call
Revenue
$343.00M
▲ 13.6% YoY
Diluted EPS
$0.98
▲ 600% YoY
Gross margin
85.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Indivior Pharmaceuticals, Inc. (INDV) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-30
Indivior Pharmaceuticals, Inc. (INDV) Q1 2026 Earnings Call Transcript
Confident tone SUBLOCADE U.S. growth 2026 financial guidance raise Pipeline setbacks
Revenue
$317.00M
▲ 19.2% YoY
Diluted EPS
$0.69
▲ 81.6% YoY
Gross margin
87.4%
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Indivior Pharmaceuticals, Inc. (INDV) Q4 2025 Earnings Call Transcript
Confident tone SUBLOCADE Commercial Performance Indivior Action Agenda / Phase 2 Accelerate 2026 Financial Guidance and Capital Deployment
Revenue
$357.00M*
▲ 19.8% YoY
Gross margin
82.1%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Indivior Pharmaceuticals, Inc. (INDV) Q3 2025 Earnings Call Transcript
Confident tone SUBLOCADE commercial execution and growth Indivior Action Agenda phasing (Phase I, II, III) Organizational simplification and cost reduction
Revenue
$314.00M
▲ 2.3% YoY
Diluted EPS
$0.33
▲ 106.2% YoY
Gross margin
73.2%
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-07-31
Indivior Pharmaceuticals, Inc. (INDV) Q2 2025 Earnings Call Transcript
Positive tone SUBLOCADE U.S. commercial execution Indivior Action Agenda (operational restructuring) Medicaid and policy environment
Revenue
$302.00M
▲ 1% YoY
Diluted EPS
$0.14
Gross margin
82.8%
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-04-24
Indivior Pharmaceuticals, Inc. (INDV) Q1 2025 Earnings Call Transcript
Balanced tone SUBLOCADE performance and stabilization Justice system funding headwinds Suboxone Film generic competition
Revenue
$266.00M
▼ 6.3% YoY
Diluted EPS
$0.38
▼ 15.6% YoY
Gross margin
83.1%
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–7 of 7 earnings calls
Key facts CIK 1625297 CUSIP 45579U109 13F (30d) 8 filings 8 filers Visit website Investor relations